Design, synthesis, and biological evaluation of novel histone deacetylase 6 selective inhibitors
Histone deacetylase 6 (HDAC6) is distinguished from other HDACs by its ability to deacetylate α-tubulin and HSP90, and was reported to be related to a variety of human diseases, such as cancers, neurodegenerative diseases, and immunological disorders. The discovery of novel HDAC6 selective inhibitor...
Main Authors: | Tianyi Zhang, Xiaoyan Zhao, Xiangpei Sun, Wei Tian, Chongqing Wang, Mingping Wang, Yi Zhang, Xin Chen, Canhui Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-05-01
|
Series: | Journal of Saudi Chemical Society |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1319610322000321 |
Similar Items
-
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives
by: Jingjing Pu, et al.
Published: (2024-04-01) -
Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
by: Masumeh Sanaei, et al.
Published: (2019-01-01) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
by: Monica Phimmachanh, et al.
Published: (2020-10-01) -
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
by: Tandon N, et al.
Published: (2016-05-01) -
Histone Deacetylases and their Inhibitors in Cancer Epigenetics
by: Kelly N. Hassell
Published: (2019-11-01)